Hepa1-6 / Hepa1-6-luc Orthotopic Mouse Model Service for Liver Cancer

The Hepa1-6 / Hepa1-6-luc orthotopic mouse model grows a murine hepatocellular carcinoma directly within the liver parenchyma of immunocompetent C57BL/6 hosts, preserving the Kupffer cells, macrophages, and suppressive T-cell networks that shape real HCC biology. Alfa Cytology delivers this syngeneic platform with three validated implantation routes — subcapsular inoculation, donor-tissue fragment placement, and portal vein delivery — together with luciferase-based tumor tracking in vivo, checkpoint-blockade-compatible dosing schedules, and full liver-microenvironment immunophenotyping, so immunotherapy, anti-angiogenic, and combination strategies are evaluated where they will actually act.

Overview of Hepa1-6 / Hepa1-6-luc Orthotopic Mouse Model for Liver Cancer

Hepa1-6 traces back to 1957, when the BW7756 hepatoma was induced in a C57L/J mouse with diethylnitrosamine; the clonal line was established by Bernal and colleagues in 1980 and remains, with its sister clone Hepa1c1c7, one of the most extensively used murine hepatoma lines. Although it grows readily in vitro in DMEM with 10% serum, its true value emerges in vivo: transplanted into its syngeneic C57BL/6 background, Hepa1-6 forms hepatocellular carcinomas inside an intact immune system, engaging Kupffer cells, tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells exactly as human tumors do. Orthotopic placement adds what flank xenografts cannot offer — portal circulation, lobular architecture, hypoxic gradients, and native stromal cross-talk — and the model is an established responder to anti-PD-1 therapy, making it the default workhorse for HCC immunotherapy combinations, vaccine strategies, CAR approaches, and oncolytic virus evaluation.

Fig 1. Longitudinal bioluminescence imaging of a Hepa1-6-Luc orthotopic hepatocellular carcinoma model used to evaluate CRISPR/Cas9-mediated remodeling of the immunosuppressive tumor microenvironment. (He, Lei, et al., 2024)

Methodologically, the orthotopic Hepa1-6 literature has converged on three routes with distinct behavior. Direct subcapsular inoculation of 1–3 × 10⁶ cells in 20–50 µL beneath the capsule of the left lobe produces tumors in 100% of recipients, though needle-track seeding can yield dispersed multinodular growth and occasional abdominal leakage; implanting ~1 mm³ fragments from donor subcutaneous tumors instead generates uniform, solitary, caliper-measurable nodules (averaging 0.6 ± 0.2 cm at two weeks) with 100% take rates in syngeneic hosts; and portal vein delivery, which forces cells through the hepatic sinusoids, models hematogenous seeding. Intravenous injection, by contrast, fails to establish liver tumors entirely and seeds lung and heart — a cautionary finding that underscores why surgical orthotopic technique matters. Tumors become detectable around day 10 and progress rapidly between weeks two and four, with lung metastasis emerging in a minority; importantly, intravenous injection is not a substitute for true orthotopic implantation in vivo. The Hepa1-6-luc variant enables whole-liver bioluminescence quantification from the first week, randomization at defined signals, rechallenge designs that test durable immunity after curative combination therapy, and compatibility with image-guided radiotherapy regimens.

Cell Line Information: Hepa1-6 / Hepa1-6-luc

Hepa1-6 (ATCC CRL-1830) is an adherent, epithelial-like murine hepatoma line with wild-type Trp53 and KRAS, and alpha-fetoprotein expression that rises as tumors progress — a marker that tracks disease burden in orthotopic settings. It has been carried in laboratories worldwide for more than four decades as both a transplantable tumor and a differentiation model. In syngeneic C57BL/6 hosts it is moderately immunogenic and checkpoint-responsive, while in NSG mice it grows without immune constraint for mechanistic studies. The Hepa1-6-luc derivative expresses firefly luciferase; as with other luciferase-tagged lines, monoclonal selection of high-signal clones in vitro is recommended for uniform, quantitative bioluminescence in vivo.

Our Services

Liver orthotopic work rewards methodical hands: the difference between a dispersed, leaky inoculation and a clean, solitary, measurable nodule is decided in minutes of microsurgery. Alfa Cytology performs Hepa1-6 implantation using validated subcapsular and fragment techniques, then supports each study with scheduled bioluminescence in vivo, dosing calendars built for checkpoint blockade and anti-angiogenic combinations, and endpoint panels that quantify not just tumor size but the immune landscape inside the liver — flow cytometry for infiltrating T cells and macrophages, cytokine profiling, and AFP/Ki-67 histopathology.

Workflow of Hepa1-6 / Hepa1-6-luc Orthotopic Mouse Model Construction

The Hepa1-6 orthotopic procedure is a compact, well-benchmarked operation whose quality hinges on aseptic microsurgery and controlled inoculum placement. The workflow below describes model construction from cell preparation through immune-microenvironment analysis, following configurations documented across the published literature.

1. Cell Expansion and Quality Control: Hepa1-6 or Hepa1-6-luc cells are expanded in vitro in DMEM + 10% FBS to the logarithmic phase; batches are confirmed mycoplasma-negative, STR-authenticated, and precisely counted, with monoclonal luciferase expression verified for tagged lines before implantation.
2. Donor Tumor Generation (Fragment Route): When uniform solitary nodules are required, 3 × 10⁶ cells are inoculated subcutaneously into donor C57BL/6 mice; tumors reaching ~1 cm are excised, necrotic cores are trimmed, and viable tissue is sectioned into ~1 mm³ fragments for implantation.
3. Anesthesia and Liver Exposure: Recipient mice, typically 6–8-week-old C57BL/6, are anesthetized with isoflurane or ketamine-based regimens; a subxiphoid or left subcostal incision exposes the left hepatic lobe, which is gently mobilized onto moistened gauze.
4. Orthotopic Implantation: For subcapsular inoculation, 1–3 × 10⁶ cells in 20–50 µL PBS:Matrigel (1:1) are injected slowly beneath the capsule with the needle parallel to the liver surface, held in place ~10 seconds, and the entry site is compressed with a sterile swab for about two minutes to prevent bleeding and leakage; for the fragment route, 2–3 pieces are tucked into a prepared subcapsular pocket and secured with tissue adhesive; a portal vein infusion configuration (10⁶ cells) is available for hematogenous-seeding questions.
5. Closure and Postoperative Recovery: The abdominal wall and skin are closed with 4–0 absorbable sutures; animals recover on a warming platform with analgesia per IACUC protocol and are monitored daily until fully ambulatory.
6. Tumor Monitoring and Randomization: Hepa1-6-luc tumors are imaged weekly by bioluminescence in vivo from approximately day 7–10, while non-luc configurations are followed by small-animal MRI, ultrasound, or caliper where accessible; animals are randomized into treatment arms once tumors are established (commonly day 5–10).
7. Treatment Administration: Test agents are dosed on study-defined schedules — for example, anti-PD-1 at 200 µg intraperitoneally every three days, anti-angiogenic agents from day 5, or radiotherapy fractions delivered with image guidance — with body weight and clinical condition recorded throughout.
8. Endpoint Analysis and Reporting: At termination, the liver tumor is excised, measured, and weighed; the peritoneal cavity is inspected for seeding or ascites and the lungs for metastatic nodules; tissues are processed for H&E, AFP, and Ki-67 staining, infiltrating immune populations are profiled by flow cytometry (CD8, CD4, Foxp3, macrophage markers), serum cytokines such as IFN-γ and IL-10 are quantified, and ex vivo bioluminescence confirms signal distribution in luciferase studies.

Fig 2. Hepa1-6 / Hepa1-6-luc orthotopic mouse model construction workflow.

Case Study-Hepa1-6 / Hepa1-6-luc Orthotopic Mouse Model Development

The Hepa1-6 orthotopic system is the most widely deployed syngeneic platform in preclinical HCC research, and it has carried a broad range of Alfa Cytology client programs — checkpoint blockade alone and in combination with anti-angiogenic or metabolic agents, dendritic-cell and nanoparticle vaccines with rechallenge testing, CAR and oncolytic strategies, and image-guided radiotherapy evaluation. Across these programs, readouts have combined longitudinal bioluminescence in vivo, caliper or imaging-based tumor kinetics, and liver immune-microenvironment profiling. Anonymized case summaries and representative data packages are available on request.

Why Choose Alfa Cytology?

A liver orthotopic study succeeds when surgical reproducibility, immune-competent biology, and imaging discipline converge. Alfa Cytology has structured its Hepa1-6 service around those three demands.

• An immunocompetent syngeneic liver model with an intact Kupffer cell, macrophage, and T-regulatory microenvironment.
• Three validated implantation routes — subcapsular inoculation, fragment implantation for uniform solitary nodules, and portal vein delivery — each with documented take rates.
• Monoclonal, high-signal Hepa1-6-luc banks with in vitro luciferase verification for quantitative in vivo imaging from week one.
• Established responsiveness to anti-PD-1, enabling meaningful checkpoint-combination study designs.
• Rechallenge capability for testing durable, memory-based immunity after curative combination therapy.
• Liver-specific endpoint depth: AFP and Ki-67 histopathology, TIL flow cytometry, and serum cytokine profiling.
• Compatibility with image-guided radiotherapy and advanced imaging modalities (MRI, PET-CT, ultrasound).

Contact Us

Whether your HCC program targets the checkpoint axis, tumor angiogenesis, or the liver immune microenvironment itself, the Hepa1-6 / Hepa1-6-luc orthotopic model offers the immunocompetent realism your data will be judged by — and Alfa Cytology has the surgical and imaging expertise to run it to publication standard. Contact us to review route options, combination schedules, and endpoint panels, and receive a customized study quotation.

For research use only. Not intended for any clinical use.